Home
>
Glenmark Pharmaceuticals Ltd Financials

Glenmark Pharmaceuticals Ltd Financial Statement

Glenmark Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

(Rs. CR)	Dec 2023	Sep 2023	Jun 2023
Revenue	1,623.91	2,306.99	2,193.75
Operating Expense	1,574.65	1,809.6	1,691.02
Net Profit	-20.41	302.35	271.66
Net Profit Margin	-1.26	13.11	12.38
Earning Per Share	-0.72	10.72	9.63
EBIDTA	51.18	419.61	420.91
Effective Tax Rate	-107.94	1.85	7.67

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

1,623.91

1,574.65

-20.41

-1.26

-0.72

51.18

-107.94

2,306.99

1,809.6

302.35

13.11

10.72

419.61

1.85

2,193.75

1,691.02

271.66

12.38

9.63

420.91

7.67

Glenmark Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Total Revenue Annual	12,990.11	12,304.9	10,943.93
Operating Expenses Annual	10,711.74	9,984.6	8,859.55
Operating Profit Annual	1,829.3	2,226.06	2,179.14
Interest Annual	349.58	298.1	353.11
Depreciation	611.27	486.72	443.55
Net Profit Annual	297.25	941.71	970.04
Tax Annual	491.05	447.6	412.39

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

12,990.11

10,711.74

1,829.3

349.58

611.27

297.25

491.05

12,304.9

9,984.6

2,226.06

298.1

486.72

941.71

447.6

10,943.93

8,859.55

2,179.14

353.11

443.55

970.04

412.39

Glenmark Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Cash Flow at the Beginning	1,410.53	1,138.1	1,110.28
Cash Flow from Operations	625.39	1,108.65	1,131.21
Cash Flow from Investing	-515.44	-315.73	-661.61
Cash Flow from Financing	-77.46	-520.49	-441.78
Cash Flow at the End	1,443.03	1,410.53	1,138.1

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

1,410.53

625.39

-515.44

-77.46

1,443.03

1,138.1

1,108.65

-315.73

-520.49

1,410.53

1,110.28

1,131.21

-661.61

-441.78

1,138.1

Glenmark Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
PBDIT Margin (%)	19.93	20.26	19.91
PBIT Margin (%)	15.23	16.31	15.86
PBT Margin (%)	15.16	16.23	15.79
Net PROFIT Margin (%)	14.7	24.54	21.8
Return On Networth / Equity (%)	6.91	14.36	14.77
Return On Networth /Employed(%)	14.28	15.77	14.7
Return On Assets (%)	13.38	23.31	20.27
Total Debt / Equity(X)	0.2	0.24	0.26
Asset Turnover Ratio (%)	0.91	0.95	0.93

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

19.93

15.23

15.16

14.7

6.91

14.28

13.38

0.2

0.91

20.26

16.31

16.23

24.54

14.36

15.77

23.31

0.24

0.95

19.91

15.86

15.79

21.8

14.77

14.7

20.27

0.26

0.93

Glenmark Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated

Standalone

Particulars	Mar 2023	Mar 2022	Mar 2021
Fixed Assets Annual	6,338.47	5,976.03	5,292.73
Total Current Assets Annual	9,873.72	8,282.35	7,359.58
Non Current Assets Annual	9,497.96	8,800.94	8,244
Total Shareholders Funds Annual	9,473.92	9,086.65	7,064.63
Total Assets Annual	19,371.68	17,083.29	15,603.58

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

6,338.47

9,873.72

9,497.96

9,473.92

19,371.68

5,976.03

8,282.35

8,800.94

9,086.65

17,083.29

5,292.73

7,359.58

8,244

7,064.63

15,603.58

Glenmark Pharmaceuticals Ltd Earning Calls

Dec 2023

EPS beaten by 0.00 %

Open Demat Account

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

Get Your FAQs Right

What is Glenmark Pharmaceuticals Ltd's share capital?

As of May 20, 2024, Glenmark Pharmaceuticals Ltd has a market capitalization of 13,120.82 Cr. Value Research classifies it as a Large-Cap company.

Is Glenmark Pharmaceuticals Ltd debt-free?

Yes, Glenmark Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.49.

What is Glenmark Pharmaceuticals Ltd's total revenue?

In FY 2023, Glenmark Pharmaceuticals Ltd recorded a total revenue of approximately 11,431.94 Cr marking a significant milestone in the company's financial performance.

What is the future growth of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and 0.0% annually, respectively..

What is the PE Ratio of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's current PE ratio is 44.14.

What is Glenmark Pharmaceuticals Ltd's Return on Capital Employed (ROCE)?

Glenmark Pharmaceuticals Ltd's ROCE averaged 12.9% from the FY ending March 2021 to 2023, with a median of 14.2%. It peaked at 15.2% in March 2022, reflecting strong capital efficiency over the period..

What is the latest EBIT (Earnings Before Interest and Taxes) of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's latest EBIT is Rs. 1,055.84 Cr, surpassing the average EBIT of Rs. 1,510.26 Cr over the 5 years..